<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892798</url>
  </required_header>
  <id_info>
    <org_study_id>2018-6357</org_study_id>
    <nct_id>NCT03892798</nct_id>
  </id_info>
  <brief_title>Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene</brief_title>
  <acronym>IRF2BPL</acronym>
  <official_title>Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol serves as a data collection tool for individuals with variants (missense,
      nonsense, frameshifts) in the IRF2BPL gene (MIM 611720), which causes Neurodevelopmental
      Regression, Seizures, Autism and Developmental Delay (NEDAMSS, MIM 618088) and may be
      involved in other neurodevelopmental presentations. This information will be analyzed to
      develop a better understanding of the findings and progression of symptoms in individuals
      with variants in the IRF2BPL gene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurodevelopmental Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS) is
      caused by changes in the IRF2BPL gene. Variants in the gene can also lead to other
      neurodevelopmental presentations. Due to the limited number of cases that have been described
      to date, clinicians may have a limited understanding of what types of symptoms can develop in
      affected individuals and at what age. The purpose of the study is to gather clinical
      information about progression, treatments and outcomes for patients with variants in IRF2BPL.
      The investigators will collect information about medical history, growth, development,
      treatments and the results of previous genetic tests. In some cases, the investigators may
      also collect tissue samples. This is a non-interventional study that will expand the current
      understanding of the range of health concerns that can be seen in individuals with changes in
      the IRF2BPL gene by collecting medical information and samples from a larger group of
      affected individuals.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">December 2039</completion_date>
  <primary_completion_date type="Anticipated">December 2038</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>Throughout study completion, with the assessment completed on average once per year.</time_frame>
    <description>The investigators will collect information regarding age at development of symptoms, age at diagnosis, method for diagnosis, specific mutations detected, additional complications with age at onset and treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotype-phenotype correlations</measure>
    <time_frame>Throughout study completion, with the assessment completed on average once per year.</time_frame>
    <description>The investigators will assess for correlations between the type of variant in the IRF2BPL gene, the location of the variant, and the clinical presentation and symptoms.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neurodevelopmental Regression, Seizures, Autism and Developmental Delay (NEDAMSS)</condition>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Movement Disorders</condition>
  <condition>Seizures</condition>
  <condition>Dystonia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No interventions are planned</intervention_name>
    <description>No interventions are planned</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of children and adults who are diagnosed with NEDAMSS and
        have variants in the IRF2BPL gene.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Living or deceased individuals with variants in the IRF2BPL gene

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loren Pena, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loren Pena, MD, PhD</last_name>
    <phone>513-636-4760</phone>
    <email>loren.pena@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vandana Shashi, MD</last_name>
    <phone>919-684-2036</phone>
    <email>vandana.shashi@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loren Pena, MD, PhD</last_name>
      <phone>513-636-4760</phone>
      <email>loren.pena@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Loren Pena, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marcogliese PC, Shashi V, Spillmann RC, Stong N, Rosenfeld JA, Koenig MK, Martínez-Agosto JA, Herzog M, Chen AH, Dickson PI, Lin HJ, Vera MU, Salamon N, Graham JM Jr, Ortiz D, Infante E, Steyaert W, Dermaut B, Poppe B, Chung HL, Zuo Z, Lee PT, Kanca O, Xia F, Yang Y, Smith EC, Jasien J, Kansagra S, Spiridigliozzi G, El-Dairi M, Lark R, Riley K, Koeberl DD, Golden-Grant K; Program for Undiagnosed Diseases (UD-PrOZA); Undiagnosed Diseases Network, Yamamoto S, Wangler MF, Mirzaa G, Hemelsoet D, Lee B, Nelson SF, Goldstein DB, Bellen HJ, Pena LDM. IRF2BPL Is Associated with Neurological Phenotypes. Am J Hum Genet. 2018 Sep 6;103(3):456. doi: 10.1016/j.ajhg.2018.08.010.</citation>
    <PMID>30193138</PMID>
  </reference>
  <reference>
    <citation>Tran Mau-Them F, Guibaud L, Duplomb L, Keren B, Lindstrom K, Marey I, Mochel F, van den Boogaard MJ, Oegema R, Nava C, Masurel A, Jouan T, Jansen FE, Au M, Chen AH, Cho M, Duffourd Y, Lozier E, Konovalov F, Sharkov A, Korostelev S, Urteaga B, Dickson P, Vera M, Martínez-Agosto JA, Begemann A, Zweier M, Schmitt-Mechelke T, Rauch A, Philippe C, van Gassen K, Nelson S, Graham JM Jr, Friedman J, Faivre L, Lin HJ, Thauvin-Robinet C, Vitobello A. De novo truncating variants in the intronless IRF2BPL are responsible for developmental epileptic encephalopathy. Genet Med. 2019 Apr;21(4):1008-1014. doi: 10.1038/s41436-018-0143-0. Epub 2018 Aug 31.</citation>
    <PMID>30166628</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Medical Center, Cincinnati</investigator_affiliation>
    <investigator_full_name>Loren Pena</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>IRF2BPL</keyword>
  <keyword>NEDAMSS</keyword>
  <keyword>dystonia</keyword>
  <keyword>movement disorder</keyword>
  <keyword>seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

